DETAILED NOTES ON HEMGENIX

Amount of qualified patients: CDEC discussed the uncertainty in the amount of individuals with moderately extreme to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical gurus consulted by CADTH indicated that some people who will be labeled as obtaining delicate or reasonable condition could have a extreme bleeding phen